Clinical Trial Update: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) [Phase 3]

View source ↗

Summary

An open-label, single-arm Phase 3 study to evaluate pharmacokinetics and safety of subcutaneous sonelokimab in adolescents with moderate to severe hidradenitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: RECRUITING